Boston Scientific's EKOS System Cuts Pulmonary Embolism Mortality by 61% in HI-PEITHO Trial

Why It Matters

The HI‑PEITHO trial provides the first high‑quality randomized evidence that a catheter‑directed, ultrasound‑assisted approach can outperform anticoagulation alone for intermediate‑risk pulmonary embolism. This could trigger a paradigm shift in PE management, moving the therapeutic focus from purely medical therapy to a hybrid model that leverages minimally invasive technology. By demonstrating comparable safety—no increase in major bleeding—and shorter hospitalizations, the EKOS system addresses two major cost drivers in acute PE care: intensive care utilization and prolonged inpatient stays. If guideline committees incorporate EKOS as a first‑line option, hospitals will need to invest in training and equipment, creating a new revenue stream for device manufacturers while potentially lowering overall system costs. Moreover, the trial’s success may spur further innovation in ultrasound‑facilitated drug delivery across other vascular territories, expanding the therapeutic toolbox for clinicians and accelerating the adoption of precision interventional therapies in cardiovascular medicine.

Key Takeaways

• HI‑PEITHO enrolled 544 intermediate‑risk PE patients at 59 U.S. and European sites.
• Primary 7‑day composite endpoint: 4.0% with EKOS + anticoagulation vs. 10.3% with anticoagulation alone (61% reduction, P=0.005).
• Cardiorespiratory decompensation: 3.7% vs. 10.3%; no intracranial bleeding through 30 days.
• Trial presented at ACC.26 and published in NEJM, providing first randomized data for catheter‑directed PE therapy.
• Potential $200‑$300 million annual revenue uplift for Boston Scientific if EKOS captures 5% of U.S. intermediate‑risk PE cases.

Pulse Analysis

The EKOS data arrives at a time when the PE market is ripe for disruption. Anticoagulation, while effective, leaves a sizable residual risk of hemodynamic collapse, especially in the intermediate‑risk cohort that makes up roughly one‑third of all acute PE presentations. By delivering low‑dose thrombolytics directly to the clot and using ultrasound to enhance penetration, EKOS addresses the core limitation of systemic therapy—inefficient drug delivery—without the bleeding penalties associated with full‑dose systemic thrombolysis.

Historically, catheter‑directed therapies have struggled to gain traction due to limited trial data and concerns over procedural complexity. HI‑PEITHO changes that narrative by delivering statistically robust outcomes across a diverse, multinational patient pool. The 61% relative risk reduction is not merely a statistical win; it translates into tangible clinical benefits—fewer ICU admissions, shorter hospital stays, and reduced downstream complications. For payers, the cost offset from avoided critical care could outweigh the device’s acquisition cost, making EKOS an attractive proposition in value‑based care models.

Looking ahead, the real test will be guideline adoption and real‑world uptake. If the ACC and ESC endorse EKOS as a first‑line option, we can expect a rapid diffusion curve, especially in high‑volume tertiary centers that already have interventional cardiology or radiology suites equipped for such procedures. Boston Scientific’s partnership with the PERT Consortium positions the company to lead educational initiatives, further cementing its market foothold. Competitors will likely accelerate their own ultrasound‑assisted platforms, intensifying a technology arms race that could drive down costs and spur incremental innovations, such as next‑generation catheters with integrated imaging. In sum, the HI‑PEITHO trial not only validates EKOS clinically but also sets the stage for a broader transformation in how acute PE is treated, with ripple effects across device development, hospital economics, and patient outcomes.